Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus NYSTAFORM.
HALOTEX vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal